Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander E Perl

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Hematology. American Society of Hematology. Education Program|December 10, 2017
The role of targeted therapy in the management of patients with AMLAlexander E Perl
Current Opinion in Hematology|December 27, 2017
The most novel of the novel agents for acute myeloid leukemiaAlexander E Perl
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Improving Response to FLT3 Inhibitors-BCL2 the Rescue?Alexander E Perl
Blood|November 14, 2024
Approaching a therapeutic inflection point for FLT3-mutated AMLAlexander E Perl
Best Practice & Research. Clinical Haematology|March 25, 2021
Which novel agents will have a clinically meaningful impact in AML at diagnosis?Alexander E Perl
Blood Advances|January 4, 2018
The role of targeted therapy in the management of patients with AMLAlexander E Perl
Blood|June 28, 2019
Availability of FLT3 inhibitors: how do we use them?Alexander E Perl
Current Treatment Options in Oncology|December 22, 2007
Exploiting signal transduction pathways in acute myelogenous leukemiaAlexander E Perl, Martin Carroll
Blood Advances|March 26, 2020
Gilteritinib: potent targeting of FLT3 mutations in AMLMark Levis, Alexander E Perl
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2022
Shall We Dance: Evolving Partnerships of Targeted Therapies for AMLAlexander E Perl, Paresh Vyas
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Hematology. American Society of Hematology. Education Program|December 10, 2017
The role of targeted therapy in the management of patients with AMLAlexander E Perl
Current Opinion in Hematology|December 27, 2017
The most novel of the novel agents for acute myeloid leukemiaAlexander E Perl
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Improving Response to FLT3 Inhibitors-BCL2 the Rescue?Alexander E Perl
Blood|November 14, 2024
Approaching a therapeutic inflection point for FLT3-mutated AMLAlexander E Perl
Best Practice & Research. Clinical Haematology|March 25, 2021
Which novel agents will have a clinically meaningful impact in AML at diagnosis?Alexander E Perl
Blood Advances|January 4, 2018
The role of targeted therapy in the management of patients with AMLAlexander E Perl
Blood|June 28, 2019
Availability of FLT3 inhibitors: how do we use them?Alexander E Perl
Current Treatment Options in Oncology|December 22, 2007
Exploiting signal transduction pathways in acute myelogenous leukemiaAlexander E Perl, Martin Carroll
Blood Advances|March 26, 2020
Gilteritinib: potent targeting of FLT3 mutations in AMLMark Levis, Alexander E Perl
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2022
Shall We Dance: Evolving Partnerships of Targeted Therapies for AMLAlexander E Perl, Paresh Vyas
Pageof 9